AzTrials
AzTrials

Pulmonary HypertensionReserveNCT04188756

RV Systolic and Diastolic Function and Contractile Reserve Under Acute Exercise and in Response to Chronic Exercise-based Rehabilitation

A study testing Exercise in people with Pulmonary Hypertension and Right Heart Failure, run by University of Giessen at 1 site in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Exercise training in Pulmonary arterial hypertension in the setting of rehabilitation leads to an enormous improvement of functional state and haemodynamics. However the underlying mechanism is still unkown. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
84 participants
Where
1 siteGermany
Study dates
1 Jul 2022to 1 Jul 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Consent form,
  • men and women> 18 years <75 years
  • invasively confirmed chronic PH who have received complete diagnostic evaluation by specialized physicians according to at a center for pulmonary hypertension and were adjusted for 2 months under intensive medical therapy and are stable

Who cannot join

  • Pregnancy or lactation,
  • Change in medication during the last 2 months,
  • Patients with signs of right heart decompensation, severe walking disturbance,
  • No previous invasively confirmation of PH, acute diseases, Infections, fever,
  • active myocarditis, unstable angina pectoris, exercise-induced ventricular -arrhythmias, congestive heart failure, significant heart disease, pacemakers, and -hypertrophic obstructive cardiomyopathy, or a highly reduced left ventricular function

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • University Hospital Giessen

    Giessen, 35392

    Khodr Tello, MD, 004964198556087, khodr.tello@innere.med.uni-giessen.de

    Manuel Richter, MD, 004964198556022, manuel.richter@innere.med.uni-giessen.de

Other trials in Germany

About this study

Exercise training in Pulmonary arterial hypertension in the setting of rehabilitation leads to an enormous improvement of functional state and haemodynamics. However the underlying mechanism is still unkown. It is assumed to be relied on Right ventricular contractile reserve, but this has never been proven with goldstandard PV-loop assessment.

Our aim is to evaluate the mechanism leading to the increase in functional state and to evaluate the impact of exercise (acute and chronic) on right ventricular performance

Read the detailed description

The ability of the RV to increase Ees under exercise is barely understood, and it is not known whether this is accompanied by changes in Eed. Exercise-based rehabilitation programs in PAH patients showed a marked increase in 6 Minute Walk distance and CI; the improvement was, partially higher than the improvement upon targeted PAH medication Several mechanisms may underlie such improvement, in particular a decrease in PVR, improved peripheral muscular function and improved systolic and/or diastolic RV function. To assess the latter aspect in a load-independent fashion, the investigators will perform acute exercising and exercise-based rehabilitation in PAH patients with performance of RV PV loop measurements, which has never been undertaken under this aspect in PAH patients.

Acute exercising: As "physiological response" to acute exercising, an increase in RV Ees is to be expected. However, based on clinical experience and on the surprising finding of an Ees decrease upon volume challenge in patients with low Ees/Ea values, the investigators hypothesize that orientation and extent of the Ees response to acute exercise will depend on the baseline Ees/Ea: patients with well-maintained Ees/Ea values may reveal an increase of Ees in response to acute exercise, whereas patients with RV-PA uncoupling (baseline Ees/Ea < 0.8) may show an acute heterometric adaptation with increase in volumes and decrease in Ees (negative ∆ Ees). Moreover, this study may again provide a novel "threshold of uncoupling" (Ees/Ea ratio), at which the RV response to acute exercising switches from increased to decreased contractility. The investigators will use incremental exercise tests (step or ramp protocol; handgrip protocol) with repeated hemodynamic measurements with right heart catheterization (RHC) and PV-loop catheter. The modified single beat method will be used to calculate Ees and Ea as well as Eed under exercise: the intercept on the x-axis will be predefined by Valsalva maneuver and preload reduction, and this point will be the reference for PV-loop-derived ESPVR to calculate Ees as decribed before. The study will include 42 PAH patients, who will subsequently be entered into the rehabilitation program (for power calculation see below). Similar to the volume challenge study, the hypothesis is that extent and orientation of ∆ Ees upon acute exercise are correlated with baseline Ees/Ea. Primary endpoint: ∆ Ees between baseline and maximum exercise. Secondary endpoints: time to recovery of Ees and RV-EDV after acute exercising, changes in PVR, mPAP, CI, Eed, Ea, Stroke Work, EDP, ESV, EDV and SV. Statistics: the primary endpoint will be analyzed by descriptive statistics, graphical representations with scatterplots, quantitative measures of dependence (Pearson's r or Spearman´s rho) and description of conditional distributions will be used.

Exercise-based rehabilitation - the RESERVE study: The investigators aim to conduct a single center, interventional, randomized, non-blinded, prospective study to evaluate the impact of exercise training on RV-PA- coupling. Every patient will undergo acute exercise testing during first catheterization as described above. Thereafter, patients will be randomly assigned to a control and a training group for chronic exercise in a rehabilitation program. Medication will remain unchanged during the study period. After 15 weeks, RHC and PV-loop assessment at baseline and in response to acute exercise will be repeated. During the study, patients of the control group will not receive any advice on exercise training. Rehabilitation-exercise training will consist of High Intensity Interval Training (HIIT) as described before . Retesting (baseline, response to exercise) will be performed after 15 weeks. Different examinations will be performed at the different visits. Primary endpoint will be the change in baseline Ees over the 15 weeks observation period. Secondary endpoints include the Ees response to acute exercising as well as further PV-loop, cMRI, Echo-derived and functional parameters as detailed in Table 2. Statistics: Continuous variables will be compared using repeated-measures ANOVA for differences between values at baseline and after acute and chronic exercise challenge. The comparisons of characteristics at baseline and after exercise between the two groups, as well as the comparisons of the absolute changes of variables from baseline to post-exercise between groups will be analyzed by adequate descriptive statistics.

Being tested
Exercise
Medical subject headings
Hypertension, Pulmonary, Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExerciseOther

    High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension

Study groups in NCT04188756
Study groupRoleWhat they receive
ExerciseOtherGroup under exercise training for 15 weeks with High intenstiy interval training under medical control
Receives: Other: Exercise
ControlNo interventionGroup with standard care according to current guidelines

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary endpoint will be the change in baseline Ees over the 15 weeks observation period

    Ees(endsystolic elastance) is a measure of coontractility

    Measured: over 15 weeks

Secondary outcomes (8)
  1. Global longitudinal strain

    Cardiac MRI measures of function, expressed in %

    Measured: over 15 weeks

  2. PVR

    Right Heart catheter measures of afterload, expressed in Wood Units

    Measured: April 2020 until July 2022

  3. Walking distance in 6MW

    functional state, expressed in meter

    Measured: over 15 weeks

  4. TAPSE,

    Echocardiography measure of function, expressed in mm

    Measured: over 15 weeks

  5. mPAP

    Pressure in Right heart catheter, expressed in mmHg

    Measured: over 15 weeks

  6. Cardiac Output

    Functional parameter, expressed in liter per minute

    Measured: over 15 weeks

  7. T1 mapping

    Cardiac MRI parameter, expressed in ms

    Measured: over 15 weeks

  8. Fractional area change

    Echocardiography measure of function, expressed in %

    Measured: over 15 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2019
  2. Study start1 Jul 2022 (estimated)
  3. Primary completion1 Feb 2023 (estimated)
  4. Study completion1 Jul 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Model description
Patients will randomized for exercice (1:1). After 15 weeks the group without exercise will be offered to take part in an exercise training
Masking
None (open label)
Enrolment
84 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04188756
Sponsor's protocol ID
UniGiessenReserve
Acronym
Reserve
Status last verified
Nov 2021
First submitted
26 Nov 2019
Last updated
9 Nov 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise in people with Pulmonary Hypertension and Right Heart Failure, run by University of Giessen at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary endpoint will be the change in baseline Ees over the 15 weeks observation period (time frame: over 15 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in